Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2026 08:30 ET | Source: OPKO Health, Inc.

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement...
April 30, 2026 08:00 ET | Source: OPKO Health, Inc.

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the...
April 28, 2026 16:05 ET | Source: OPKO Health, Inc.

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the...
April 22, 2026 08:00 ET | Source: OPKO Health, Inc.

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of...
April 21, 2026 16:05 ET | Source: OPKO Health, Inc.

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S....
April 08, 2026 08:00 ET | Source: OPKO Health, Inc.

OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19

WESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical...
February 27, 2026 08:00 ET | Source: OPKO Health, Inc.

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11,...
February 26, 2026 16:05 ET | Source: OPKO Health, Inc.

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces...
February 12, 2026 08:00 ET | Source: OPKO Health, Inc.

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the...
February 04, 2026 08:00 ET | Source: OPKO Health, Inc.

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to...